Fortress Biotech Inc
NASDAQ:FBIO

Watchlist Manager
Fortress Biotech Inc Logo
Fortress Biotech Inc
NASDAQ:FBIO
Watchlist
Price: 3.4 USD -2.3% Market Closed
Market Cap: $105.5m

Net Margin

-8.6%
Current
Improving
by 81%
vs 3-y average of -89.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-8.6%
=
Net Income
$-5.3m
/
Revenue
$62.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-8.6%
=
Net Income
$-5.3m
/
Revenue
$62.3m

Peer Comparison

Country Company Market Cap Net
Margin
US
Fortress Biotech Inc
NASDAQ:FBIO
106.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
31th
Based on 15 072 companies
31th percentile
-8.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Fortress Biotech Inc
Glance View

Market Cap
105.5m USD
Industry
Biotechnology

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 173 full-time employees. The company went IPO on 2011-11-17. Fortress has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, and at its partner companies. Its product candidates span six market areas, including oncology, rare diseases and gene therapy. The firm's commercialized products include Ximino, Targadox, Exelderm, Ceracade, Luxamend and Accutane. Its late-stage product candidates include Intravenous (IV) Tramadol, CUTX-101, MB-107 and MB-207, Cosibelimab, CK-101, CAEL-101, Triplex and CEVA101. Its product candidates also consist of MB-102 (CD123 CAR T for BPDCN), MB-101 (IL13Ra2 CAR T for Glioblastoma), MB-104, MB-106, MB-103, AVTS-001, CK-103 and ConVax. The firm operates in two operating and reportable segments: Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

FBIO Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-8.6%
=
Net Income
$-5.3m
/
Revenue
$62.3m
What is Fortress Biotech Inc's current Net Margin?

The current Net Margin for Fortress Biotech Inc is -8.6%, which is above its 3-year median of -89.6%.

How has Net Margin changed over time?

Over the last 3 years, Fortress Biotech Inc’s Net Margin has increased from -125.2% to -8.6%. During this period, it reached a low of -162.2% on Jun 30, 2023 and a high of -8.6% on Sep 30, 2025.

Back to Top